2021 Global Finalists
Synthetic biology platform - called the LysinBuilder - that uses prediction algorithms to design novel precision antibiotics in weeks instead of years. PhagoMed's lead program PM-477 is a synthetic lysin for the treatment of antibiotic-resistant Bacterial Vaginosis, which affects 100 million women globally. PM-477 kills only the bad bacteria without harming the good vaginal bacteria. Following this success, the company is now rolling out the LysinBuilder to other pathogens.